iRadimed Corporation (NASDAQ:IRMD) Receives Average Rating of “Moderate Buy” from Analysts

04 Oct 2026, 07:28 by Kim Johansen · The Markets Daily

iRadimed Corporation (NASDAQ:IRMD – Get Free Report) has been assigned an average rating of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $120.00.

A number of brokerages have recently issued reports on IRMD. Needham & Company LLC assumed coverage on iRadimed in a report on Tuesday, September 22nd. They set a “hold” rating for the company. Weiss Ratings lowered shares of iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday. Finally, Wall Street Zen downgraded shares of iRadimed from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th.

Get Our Latest Stock Analysis on iRadimed

Insider Buying and Selling at iRadimed

In related news, Director Monty K. Allen sold 1,419 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $86.41, for a total transaction of $122,615.79. Following the sale, the director directly owned 19,581 shares in the company, valued at approximately $1,691,994.21. This trade represents a 6.76% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 34.60% of the stock is owned by insiders.

Hedge Funds Weigh In On iRadimed

Institutional investors and hedge funds have recently bought and sold shares of the stock. Integrated Wealth Concepts LLC purchased a new stake in iRadimed during the 2nd quarter worth $28,000. IFP Advisors Inc boosted its position in iRadimed by 264.7% in the 2nd quarter. IFP Advisors Inc now owns 569 shares of the medical equipment provider’s stock valued at $54,000 after buying an additional 413 shares during the last quarter. Global Retirement Partners LLC purchased a new position in iRadimed in the 4th quarter valued at about $85,000. Inspire Investing LLC acquired a new stake in shares of iRadimed during the first quarter valued at about $107,000. Finally, State of Wyoming acquired a new stake in shares of iRadimed during the second quarter valued at about $130,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

iRadimed Stock Up 0.1%

NASDAQ:IRMD opened at $85.40 on Tuesday. The company has a market cap of $1.09 billion, a P/E ratio of 47.71 and a beta of 0.91. The firm’s 50 day moving average is $87.17 and its two-hundred day moving average is $91.28. iRadimed has a fifty-two week low of $70.80 and a fifty-two week high of $107.90.

iRadimed (NASDAQ:IRMD – Get Free Report) last released its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. The business had revenue of $20.47 million during the quarter, compared to the consensus estimate of $20.35 million. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Research analysts forecast that iRadimed will post 1.98 earnings per share for the current fiscal year.

iRadimed Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 28th. Shareholders of record on Friday, August 14th were paid a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date was Friday, August 14th. iRadimed’s payout ratio is currently 44.69%.

About iRadimed

(Get Free Report)

IRadimed Corporation develops, manufactures and markets medical devices designed for use in magnetic resonance imaging (MRI) environments. The company focuses on addressing the challenges of providing continuous infusion therapy and patient monitoring while patients are undergoing MRI procedures.